Hydrocortisone - Antares Pharma
Alternative Names: ATRS-1902Latest Information Update: 06 Jun 2023
At a glance
- Originator Antares Pharma
- Class Anti-inflammatories; Antiallergics; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Adrenal insufficiency
Most Recent Events
- 31 Dec 2022 Phase-III clinical trials in Adrenal insufficiency (In adults, In adolescents) in USA (Parenteral), prior to December 2022
- 24 May 2022 Antares Pharma has been acquired by Halozyme Therapeutics
- 09 Mar 2022 Antares Pharma plans a pivotal clinical trial for Adrenal insufficiency (In adults, In adolescents), in the second quarter of 2022